In August 2010, the Food and Drug Administration approved an investigational new drug (IND) clinical trial (IND 78,256) using ^{177}Lu-octreotate for patients with neuroendocrine cancers. Excel Diagnostics and Nuclear Oncology Center is the first facility in the United States to receive authorization to initiate this therapy. Dr. Ebrahim S. Delpassand is the principle investigator, and the project is in collaboration with St. Luke's Episcopal Hospital, Baylor College of Medicine, the Radio-Isotope Therapy of America Foundation, Biosynthema Inc., and Advanced Accelerator Application (*2*,*3*). So far, we have enrolled and treated 34 patients with ^{177}Lu-octreotate.

Our second active peptide receptor radionuclide therapy project under the Food and Drug Administration (IND 72,037) is for treatment of neuroendocrine cancer patients with high-dose ^{111}In-octreotide (*4*). So far, we have treated more than 110 patients with inoperable metastatic neuroendocrine cancer under this protocol. The results of our treating the first 32 patients with at least 2 cycles of 18,500-MBq (500-mCi) ^{111}In-octreotide were very promising and were published in 2008 (*5*). A manuscript describing our experience in a larger population is under review for publication.

Peptide receptor radionuclide therapy for metastatic neuroendocrine cancer using β-emitters (such as ^{177}Lu or ^{90}Y) is very promising and needs to be brought to routine clinical practice in the United States, just like in Europe (*6*).

REFERENCES

1. Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. *J Nucl Med.* 2011;52(suppl):56S–63S.
2. Excel Diagnostics and Nuclear Oncology Center Web site. Available at: http://exceldiagnostics.com/therapeutic-nuclear-medicine/. Accessed March 8, 2012.
3. Carcinoid Cancer Foundation Web site. Available at: http://carcinoid.wordpress.com/2010/08/24/. Accessed March 8, 2012.
4. RITA Foundation Web site. Available at: http://ritafoundationhouston.org/research/. Accessed March 8, 2012.
5. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. *Cancer Biother Radiopharm.* 2008;23:292–300.
6. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. *J Nucl Med.* 2011;52(suppl):42S–55S.

Peeyush Bhargava*
Ebrahim S Delpassand
**Excel Diagnostics and Nuclear Oncology Center*
9701 Richmond Ave
Houston, TX, 77042
E-mail: pbhargava@exceldiagnostics.com

Published online Mar. 15, 2012.
DOI: 10.2967/jnumed.112.104257

REPLY: We thank Drs. Bhargava and Delpassand for bringing our attention to their recent work in radiopeptide therapy of neuroendocrine tumors with ^{177}Lu and ^{111}In. We agree that the approach is very promising and needs to be brought into clinical practice in the United States, as it is now being widely used in Europe.

Michael M. Graham*
Yusuf Menda
**University of Iowa*
3863 JPP Department of Radiology
200 Hawkins Dr.
Iowa City, IA 52242-1077
E-mail: michael-graham@uiowa.edu

Published online Mar. 19, 2012.
DOI: 10.2967/jnumed.112.104323